Indications and uses
Helps prevent sunburn
TITANIUM DIOXIDE
- Manufacturer
- Guerlain
- Effective date
- 2019-12-09
- Label type
- HUMAN OTC DRUG LABEL
- Version
- 6
- Source
- legacy-cache
- Hydrated at
- 2026-08-01 23:54:24
Label at a glance#
ProductTENUE DE PERFECTION TIMEPROOF FOUNDATION WITH SUNSCREEN ULTIMATE LASTING PERFECTION BROAD SPECTRUM SPF 20 01 BEIGE PALE
Active ingredientTITANIUM DIOXIDE
Label structure11 sections
Dosage and administration
For sunscreen use: Shake well before use. Apply liberally 15 minutes before sun exposure. Reapply at least every two hours. Use a water resistant sunscreen if swimming or sweating. Sun protection measures. Spending time in the sun increases your risk of skin cancer and early skin aging. To decrease this risk, regularly use a sunscreen with a Broad Spectrum SPF value of 15 or higher and other sun protection measure...
Contacts and useful links#
Websitewww.guerlain.com
www.guerlain.com
www.guerlain.comLabel contents#
Full prescribing information#
Active ingredients
Titanium Dioxide 2.92 %
Purpose
sunscreen
Uses
- Helps prevent sunburn
Warnings
- For external use only.
• Do not use
on damaged or broken skin.
• When using this product
- keep out of eyes. Rinse with water to remove.
• Stop use and ask a doctor
if rash occurs.
• Keep out of reach of children.
If swallowed, get medical help or contact a Poison Control Center right away.
Directions
For sunscreen use:
- Shake well before use.
- Apply liberally 15 minutes before sun exposure.
- Reapply at least every two hours.
- Use a water resistant sunscreen if swimming or sweating.
- Sun protection measures. Spending time in the sun increases your risk of skin cancer and early skin aging. To decrease this risk, regularly use a sunscreen with a Broad Spectrum SPF value of 15 or higher and other sun protection measures including:
- Limit time in the sun, especially from 10 a.m.-2 p.m.
- Wear long-sleeved shirts, pants, hats, and sunglasses.
- Children under 6 months: Ask a doctor.
Inactive ingredients
AQUA (WATER) - METHYL TRIMETHICONE - DIMETHICONE - ISODODECANE - ALCOHOL - PEG-9 POLYDIMETHYLSILOXYETHYL DIMETHICONE - ACRYLATES/DIMETHICONE COPOLYMER - SILICA - BUTYLENE GLYCOL - MICA - ALUMINUM HYDROXIDE - PHENOXYETHANOL - PHENYL TRIMETHICONE - DISTEARDIMONIUM HECTORITE - SODIUM MYRISTOYL GLUTAMATE - STEARIC ACID -
GLYCERYL UNDECYL DIMETHICONE - VP/VA COPOLYMER - PROPYLENE CARBONATE - PARFUM (FRAGRANCE) - SODIUM CHLORIDE - TROMETHAMINE - BHT - BUTYLPHENYL
METHYLPROPIONAL - LINALOOL - CITRONELLOL - ALPHA-ISOMETHYL IONONE - BENZYL BENZOATE - GERANIOL - [MAY CONTAIN: CI 77891 (TITANIUM DIOXIDE) - CI 77492, CI 77491, CI 77499 (IRON OXIDES)]
Other information
- Protect this product from excessive heat and direct sun.
Question or comments?
In USA: 19 East, 57th Street, New York, NY 10022 (07856)
A PERFECT COMPLEXION... EVEN AFTER THE CLOCK STRIKES MIDNIGHT
FOR WOMEN WHO PLACE ALLURE, ELEGANCE AND PERFECTION BEFORE ALL ELSE, GUERLAIN HAS CREATED TENUE DE PERFECTION. NO MERE FOUNDATION, IT IS A MULTISENSORY ELIXIR THAT ADAPTS TO EVERY SITUATION AND ENSURES A PERFECT COMPLEXION THAT REMAINS FLAWLESS EVEN AFTER THE STROKE OF MIDNIGHT.
THREE EPHEMERAL MULTISENSORY OILS FOR DIVINE RESULTS
A FIRST FOR GUERLAIN, THE FORMULA IS BASED ON THREE ESSENTIAL OILS THAT EVAPORATE ONE AFTER THE OTHER, WITH THREE SUCCESSIVE EFFECTS ON THE SKIN: - THE FIRST OIL, THE MOST FLEETING, EVAPORATES UNDER THE FINGERS TO ENSURE PERFECT WEAR FOR THE FOUNDATION, WHICH GENTLY MELTS INTO THE SKIN. - THE SECOND OIL COATS THE SKIN MORE COMPLETELY, ALLOWING THE FOUNDATION TO GLIDE ON AND ENSURING UNIFORM COVERAGE BEFORE VANISHING INTO THE SKIN.
- THE LAST OIL IS THEN RELEASED TO SETTLE AND FIX THE TIMEPROOF COMPLEX LIGHTLY ON THE SKIN ENSURING THAT THE FOUNDATION REMAINS IN PLACE FOR HOURS ON END.
ULTIMATE CORRECTION, ULTIMATE WEAR: THE TIMEPROOF COMPLEX
THE CULMINATION OF GUERLAIN'S EXPERTISE, THIS SOPHISTICATED TECHNOLOGY OF ABSORBENT POWDERS AND CORRECTIVE PIGMENTS SETS TO WORK INSTANTLY, TURNING THE TEXTURE OF THE SKIN VELVETY SOFT AND ENSURING FLAWLESS COVERAGE IN ALL SITUATIONS:
- FOR ULTIMATE CORRECTION, TWO SOFT-FOCUS MICRO-POWDERS PROVIDE COMPLEMENTARY PROPERTIES: THE FIRST, IN THE FORM OF FLECKS, ENVELOPS THE CONTOURS OF THE SKIN TO SMOOTH ITS SURFACE; THE SECOND'S SPHERICAL SHAPE "ROLLS" OVER THE SKIN TO SMOOTH OUT THE APPEARANCE OF FINE LINES AND SOFTEN IMPERFECTIONS.
- FOR IMPECCABLE WEAR, CONCENTRATED PIGMENTS AND ABSORBENT BEADS ARE ENCAPSULATED IN A POLYMER THAT ROLLS ONTO THE SKIN, FORMING A SUPPLE AND UNIFORM VEIL THAT HOLDS FOR HOURS ON END. BEADS OF SILICA FURTHER THE EFFECT BY CAPTURING ANY EXCESS SEBUM, KEEPING THE VEIL INTACT, WHILE THE SPHERICAL MICRO-POWDER HELPS STABLISE THE COLOUR, ENSURING THAT IT DOES NOT CHANGE OR DARKEN.
THE ULTIMATE BEAUTY OF SMOOTH, EVEN-TONED, VELVETY SKIN IS INSTANTLY REVEALED.
INTO THE EVENING AND BEYOND, THE COMPLEXION STAYS IMPECCABLY FRESH AND VIBRANT, AS PERFECT AS WHEN IT WAS FIRST APPLIED.
16-HOUR HOLD REPORTED BY 93% OF WOMEN*
ALL-DAY COMFORT: 90%**
PERFECTLY CORRECTED COMPLEXION: 83%**
* SELF EVALUATION BY 15 WOMEN, AFTER DAILY APPLICATION.
** SATISFACTION TEST INCLUDING 30 WOMEN, IMMEDIATE RESULTS AND AFTER FOUR WEEKS OF DAILY APPLICATION.
© COPYRIGHT GUERLAIN
68, CHAMPS-ELYSEES 75008 PARIS
MADE IN FRANCE
www.guerlain.com 9 M
PACKAGE LABEL.PRINCIPAL DISPLAY PANEL
01 BEIGE PALE
3 346470 416895
REPIQUAGE USINE
GUERLAIN TENUE DE PERFECTION TIMEPROOF FOUNDATION WITH SUNSCREEN ULTIMATE LASTING PERFECTION BROAD SPECTRUM SPF 20 01 BEIGE PALE 30ml e 1 FL OZ
GUERLAIN TENUE DE PERFECTION TIMEPROOF FOUNDATION WITH SUNSCREEN ULTIMATE LASTING PERFECTION BROAD SPECTRUM SPF 20 01 BEIGE PALE
DailyMed Socrata Ingredients#
| Ingredient | Type | UNII | SPL version | Uploaded |
|---|---|---|---|---|
| TITANIUM DIOXIDE | ACTIVE INGREDIENT | 15FIX9V2JP | 5 | |
| TITANIUM DIOXIDE | ACTIVE MOIETY | 15FIX9V2JP | 5 | |
| .BETA.-CITRONELLOL, (R)- | INACTIVE INGREDIENT | P01OUT964K | 5 | |
| ALCOHOL | INACTIVE INGREDIENT | 3K9958V90M | 5 | |
| ALUMINUM HYDROXIDE | INACTIVE INGREDIENT | 5QB0T2IUN0 | 5 | |
| BENZYL BENZOATE | INACTIVE INGREDIENT | N863NB338G | 5 | |
| BUTYLATED HYDROXYTOLUENE | INACTIVE INGREDIENT | 1P9D0Z171K | 5 | |
| BUTYLPHENYL METHYLPROPIONAL | INACTIVE INGREDIENT | T7540GJV69 | 5 | |
| COPOVIDONE K25-31 | INACTIVE INGREDIENT | D9C330MD8B | 5 | |
| DIMETHICONE | INACTIVE INGREDIENT | 92RU3N3Y1O | 5 | |
| DISTEARDIMONIUM HECTORITE | INACTIVE INGREDIENT | X687XDK09L | 5 | |
| FERRIC OXIDE RED | INACTIVE INGREDIENT | 1K09F3G675 | 5 | |
| FERRIC OXIDE YELLOW | INACTIVE INGREDIENT | EX438O2MRT | 5 | |
| FERROSOFERRIC OXIDE | INACTIVE INGREDIENT | XM0M87F357 | 5 | |
| GERANIOL | INACTIVE INGREDIENT | L837108USY | 5 | |
| ISODODECANE | INACTIVE INGREDIENT | A8289P68Y2 | 5 | |
| ISOMETHYL-.ALPHA.-IONONE | INACTIVE INGREDIENT | 9XP4LC555B | 5 | |
| LINALOOL, (+/-)- | INACTIVE INGREDIENT | D81QY6I88E | 5 | |
| METHYL TRIMETHICONE | INACTIVE INGREDIENT | S73ZQI0GXM | 5 | |
| MICA | INACTIVE INGREDIENT | V8A1AW0880 | 5 | |
| PEG-9 POLYDIMETHYLSILOXYETHYL DIMETHICONE | INACTIVE INGREDIENT | TYP81E471F | 5 | |
| PHENOXYETHANOL | INACTIVE INGREDIENT | HIE492ZZ3T | 5 | |
| PHENYL TRIMETHICONE | INACTIVE INGREDIENT | DR0K5NOJ4R | 5 | |
| PROPYLENE CARBONATE | INACTIVE INGREDIENT | 8D08K3S51E | 5 | |
| SILICON DIOXIDE | INACTIVE INGREDIENT | ETJ7Z6XBU4 | 5 | |
| SODIUM CHLORIDE | INACTIVE INGREDIENT | 451W47IQ8X | 5 | |
| SODIUM MYRISTOYL GLUTAMATE | INACTIVE INGREDIENT | AYU7QD893W | 5 | |
| STEARIC ACID | INACTIVE INGREDIENT | 4ELV7Z65AP | 5 | |
| TROMETHAMINE | INACTIVE INGREDIENT | 023C2WHX2V | 5 | |
| WATER | INACTIVE INGREDIENT | 059QF0KO0R | 5 |
Products#
Every source-derived product name is available through these pages.
- TENUE DE PERFECTION TIMEPROOF FOUNDATION WITH SUNSCREEN ULTIMATE LASTING PERFECTION BROAD SPECTRUM SPF 20 01 BEIGE PALE
- TITANIUM DIOXIDE
- WATER
- METHYL TRIMETHICONE
- DIMETHICONE
- ISODODECANE
- ALCOHOL
- PEG-9 POLYDIMETHYLSILOXYETHYL DIMETHICONE
- SILICON DIOXIDE
- MICA
- ALUMINUM HYDROXIDE
- PHENOXYETHANOL
- PHENYL TRIMETHICONE
- DISTEARDIMONIUM HECTORITE
- SODIUM MYRISTOYL GLUTAMATE
- STEARIC ACID
- COPOVIDONE K25-31
- PROPYLENE CARBONATE
- SODIUM CHLORIDE
- TROMETHAMINE
- BUTYLATED HYDROXYTOLUENE
- BUTYLPHENYL METHYLPROPIONAL
- LINALOOL, (+/-)-
- .BETA.-CITRONELLOL, (R)-
- ISOMETHYL-.ALPHA.-IONONE
- BENZYL BENZOATE
- GERANIOL
- FERRIC OXIDE YELLOW
- FERRIC OXIDE RED
- FERROSOFERRIC OXIDE
NDC Codes#
| Product NDC | Package NDC |
|---|---|
| 49817-0067 | 49817-0067-1, 49817-0067-2 |
Ingredients#
Every source-derived ingredient row is available through these pages.
Source Document#
Inactive ingredient matches#
Inactive Ingredient Database values describe FDA-listed use contexts. The match method and ambiguity count are shown because ingredient names, routes, and dosage forms are not always unique. Browse recovered IID releases and source provenance.
| DailyMed ingredient | IID ingredient | UNII | Dosage form / route | Potency | Maximum daily exposure | Match |
|---|---|---|---|---|---|---|
| ALCOHOL | ALCOHOL | 3K9958V90M | SOLUTION / RESPIRATORY (INHALATION) | 0.08 %w/v | ||
| SODIUM CHLORIDE | SODIUM CHLORIDE | 451W47IQ8X | INJECTION, SOLUTION / INTRAVESICAL | 351 mg | ||
| SODIUM CHLORIDE | SODIUM CHLORIDE | 451W47IQ8X | INJECTION / PERIDURAL | 8.07 mg | ||
| ALCOHOL | ALCOHOL | 3K9958V90M | SOLUTION / TRANSDERMAL | 49.37 %w/v | ||
| SODIUM CHLORIDE | SODIUM CHLORIDE | 451W47IQ8X | SYSTEM / IONTOPHORESIS | 3.1 mg | ||
| SODIUM CHLORIDE | SODIUM CHLORIDE | 451W47IQ8X | ENEMA / RECTAL | 0.7 %w/w | ||
| SILICON DIOXIDE | SILICON DIOXIDE | ETJ7Z6XBU4 | FILM, EXTENDED RELEASE / TRANSDERMAL | 49 mg | ||
| SODIUM CHLORIDE | SODIUM CHLORIDE | 451W47IQ8X | INJECTION, SOLUTION / SUBCUTANEOUS | 1486 mg | ||
| SODIUM CHLORIDE | SODIUM CHLORIDE | 451W47IQ8X | GEL / OPHTHALMIC | 0.9 %w/v | ||
| TROMETHAMINE | TROMETHAMINE | 023C2WHX2V | INJECTION / INTRA-ARTERIAL | 562 mg | ||
| ALUMINUM HYDROXIDE | ALUMINUM HYDROXIDE | 5QB0T2IUN0 | OINTMENT / TOPICAL | NA | ||
| SODIUM CHLORIDE | SODIUM CHLORIDE | 451W47IQ8X | SUSPENSION / TOPICAL | 0.32 %w/v | ||
| SODIUM CHLORIDE | SODIUM CHLORIDE | 451W47IQ8X | DROPS / ORAL | NA | ||
| BUTYLATED HYDROXYTOLUENE | BUTYLATED HYDROXYTOLUENE | 1P9D0Z171K | FILM, SOLUBLE / ORAL | 0.06 mg | ||
| SODIUM CHLORIDE | SODIUM CHLORIDE | 451W47IQ8X | SUSPENSION / RESPIRATORY (INHALATION) | 43 mg | ||
| SILICON DIOXIDE | SILICON DIOXIDE | ETJ7Z6XBU4 | DROPS / ORAL | NA | ||
| FERROSOFERRIC OXIDE | FERROSOFERRIC OXIDE | XM0M87F357 | CAPSULE / ORAL | 11 mg | ||
| SODIUM CHLORIDE | SODIUM CHLORIDE | 451W47IQ8X | IMPLANT / SUBCUTANEOUS | 77 mg | ||
| SILICON DIOXIDE | SILICON DIOXIDE | ETJ7Z6XBU4 | CREAM / VAGINAL | 51 mg | ||
| ALCOHOL | ALCOHOL | 3K9958V90M | AEROSOL, SPRAY / TOPICAL | 561 mg | ||
| FERRIC OXIDE RED | FERRIC OXIDE RED | 1K09F3G675 | CAPSULE / ORAL | 5 mg | ||
| SODIUM CHLORIDE | SODIUM CHLORIDE | 451W47IQ8X | SUSPENSION/ DROPS / TOPICAL | 0.23 %w/v | ||
| SILICON DIOXIDE | SILICON DIOXIDE | ETJ7Z6XBU4 | POWDER / ORAL | 602 mg | ||
| FERRIC OXIDE RED | FERRIC OXIDE RED | 1K09F3G675 | TABLET, ORALLY DISINTEGRATING, DELAYED RELEASE / ORAL | 0.15 mg | ||
| SODIUM CHLORIDE | SODIUM CHLORIDE | 451W47IQ8X | INJECTION / INTRATUMOR | 1.2 %w/v | ||
| FERROSOFERRIC OXIDE | FERROSOFERRIC OXIDE | XM0M87F357 | CAPSULE, COATED / ORAL | 0.11 mg | ||
| SODIUM CHLORIDE | SODIUM CHLORIDE | 451W47IQ8X | POWDER, FOR SOLUTION / OPHTHALMIC | 0.9 %w/w | ||
| SODIUM CHLORIDE | SODIUM CHLORIDE | 451W47IQ8X | INHALANT / RESPIRATORY (INHALATION) | 3 mg | ||
| FERROSOFERRIC OXIDE | FERROSOFERRIC OXIDE | XM0M87F357 | TABLET, COATED / ORAL | NA | ||
| COPOVIDONE K25-31 | COPOVIDONE K25-31 | D9C330MD8B | TABLET / ORAL | 6374 mg | ||
| BUTYLATED HYDROXYTOLUENE | BUTYLATED HYDROXYTOLUENE | 1P9D0Z171K | INJECTION, SOLUTION / INTRAVENOUS | NA | ||
| SILICON DIOXIDE | SILICON DIOXIDE | ETJ7Z6XBU4 | TABLET, ORALLY DISINTEGRATING, DELAYED RELEASE / ORAL | 69 mg | ||
| SODIUM CHLORIDE | SODIUM CHLORIDE | 451W47IQ8X | SUSPENSION / ENDOTRACHEAL | 7.6 mg | ||
| TROMETHAMINE | TROMETHAMINE | 023C2WHX2V | SOLUTION / URETHRAL | 0.12 %w/v | ||
| BUTYLATED HYDROXYTOLUENE | BUTYLATED HYDROXYTOLUENE | 1P9D0Z171K | GUM, CHEWING / BUCCAL | 5 mg | ||
| ALCOHOL | ALCOHOL | 3K9958V90M | SPRAY / SUBLINGUAL | 397 mg | ||
| ALCOHOL | ALCOHOL | 3K9958V90M | INJECTION, EMULSION / INTRAVENOUS | 520 mg | ||
| SODIUM CHLORIDE | SODIUM CHLORIDE | 451W47IQ8X | INJECTION, POWDER, FOR SOLUTION / INTRATHECAL | 1.35 mg | ||
| COPOVIDONE K25-31 | COPOVIDONE K25-31 | D9C330MD8B | TABLET, EXTENDED RELEASE / ORAL | 300 mg | ||
| SODIUM CHLORIDE | SODIUM CHLORIDE | 451W47IQ8X | POWDER / RESPIRATORY (INHALATION) | NA | ||
| SODIUM CHLORIDE | SODIUM CHLORIDE | 451W47IQ8X | INJECTION, SOLUTION, CONCENTRATE / INTRAVENOUS | 0.86 %w/v | ||
| SILICON DIOXIDE | SILICON DIOXIDE | ETJ7Z6XBU4 | GRANULE / ORAL | 5000 mg | ||
| PHENOXYETHANOL | PHENOXYETHANOL | HIE492ZZ3T | GEL / TOPICAL | 14 mg | ||
| SODIUM CHLORIDE | SODIUM CHLORIDE | 451W47IQ8X | LIQUID / SUBCUTANEOUS | 0.7 %w/v | ||
| TROMETHAMINE | TROMETHAMINE | 023C2WHX2V | SOLUTION, GEL FORMING, EXTENDED RELEASE / OPHTHALMIC | 0.8 %w/w | ||
| STEARIC ACID | STEARIC ACID | 4ELV7Z65AP | TABLET, FILM COATED, EXTENDED RELEASE / ORAL | 120 mg | ||
| ALCOHOL | ALCOHOL | 3K9958V90M | CONCENTRATE / ORAL | 198 mg | ||
| ALCOHOL | ALCOHOL | 3K9958V90M | SPRAY / TOPICAL | 3633 mg | ||
| BUTYLATED HYDROXYTOLUENE | BUTYLATED HYDROXYTOLUENE | 1P9D0Z171K | TABLET, EXTENDED RELEASE / ORAL | 1 mg | ||
| PHENOXYETHANOL | PHENOXYETHANOL | HIE492ZZ3T | AEROSOL / TOPICAL | 1.05 %w/w | ||
| BENZYL BENZOATE | BENZYL BENZOATE | N863NB338G | INJECTION, SOLUTION / INTRAMUSCULAR | 750 mg | ||
| ALCOHOL | ALCOHOL | 3K9958V90M | SUSPENSION / ORAL | 681 mg | ||
| STEARIC ACID | STEARIC ACID | 4ELV7Z65AP | AEROSOL, FOAM / VAGINAL | 4 %w/w | ||
| ALCOHOL | ALCOHOL | 3K9958V90M | SOLUTION, CONCENTRATE / INTRAVENOUS | 4000 mg | ||
| SODIUM CHLORIDE | SODIUM CHLORIDE | 451W47IQ8X | INJECTION / INTRAVENOUS | 28773 mg | ||
| ALCOHOL | ALCOHOL | 3K9958V90M | AEROSOL / NASAL | 20 mg | ||
| SODIUM CHLORIDE | SODIUM CHLORIDE | 451W47IQ8X | INJECTION, POWDER, FOR SOLUTION / INTRAPLEURAL | 226 mg | ||
| FERRIC OXIDE YELLOW | FERRIC OXIDE YELLOW | EX438O2MRT | FILM / BUCCAL | 0.27 mg | ||
| BUTYLATED HYDROXYTOLUENE | BUTYLATED HYDROXYTOLUENE | 1P9D0Z171K | SPRAY / TOPICAL | 3 mg | ||
| SODIUM CHLORIDE | SODIUM CHLORIDE | 451W47IQ8X | INJECTION, SOLUTION / INTRAVENOUS | 2916 mg |
openFDA label cross-check#
OpenFDA label data provides additional search and identifier links. DailyMed’s Structured Product Label is the canonical label on FDA.report. Matching records are deduplicated before they are shown below.
| Brand | Generic | Manufacturer | SPL set ID | Effective date | Available safety fields | Join |
|---|---|---|---|---|---|---|
| ed166aee-3529-320d-e053-2995a90a7aee | 2fc52ded-1d29-44eb-b4db-e8367c1ac8e4 | 2022-11-09 | Warnings | 2fc52ded-1d29-44eb-b4db-e8367c1ac8e4 |
Reported adverse events (FAERS/openFDA)#
Adverse event summaries are temporarily unavailable. Other product information remains available.